Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the first disclosure of Phase 2 data from the C-800-23 study evaluating botensilimab (BOT), Agenus’ multifunctional ...

Logo courtesy Bot Image Inc. The Omaha-based MRI medical device company, Bot Image Inc., announced this month an addition to its line of software products aimed at assisting the detection of prostate ...

The safety run-in enrolled patients with non-metastatic solid tumors, divided into two cohorts of 10 patients each: dMMR/MSI-H and pMMR/MSS. Patients received a single dose of BOT (25 mg or 50 mg) ...

LEXINGTON, Mass., April 01, 2026--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the results of its end-of-Phase 2 (EOP2) ...

CAMBRIDGE, Mass., May 26, 2023 /PRNewswire/ -- The Eureka Clinical AI platform, from ConcertAI's TeraRecon, the advanced visualization and clinical AI SaaS category leader, now provides clinicians ...

OMAHA, Neb. and BELGRADE, Maine, Sept. 25, 2023 /PRNewswire/ -- Prostate cancer management reached a new pinnacle of precision with Bot Image's ProstatID using Bi-parametric MRI (bpMRI). The Nebrasksa ...

Initial results from NEOASIS demonstrate BOT/BAL efficacy in the neoadjuvant setting across multiple MSS and MSI-H solid tumors "These initial results from the NEOASIS study indicate that botensilimab ...

A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer Cases Colorectal Cancer Has Become the Leading Cause of ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at ...